CompletedNot Applicable

Sildenafil in Sever Intrauterine Growth Retardation

Egypt46 participantsStarted 2017-05-06

Plain-language summary

Severe fetal growth restriction (FGR) complicates approximately 0.4% of pregnancies and severely increases the risk of perinatal morbidity and mortality.Sildenafil citrate may offer a potential therapeutic strategy to improve uteroplacental blood flow in IUGR pregnancies.

Who can participate

Age range25 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • pregnancy complicated by severe IUGR \[abdominal circumference (AC)\< 5th percentile\] the gestational age \<25 weeks or an estimate of the fetal weight was \<600 gm (excluding known fetal anomaly/syndrome and/or planned termination) ( von Dadelszen.et al;2011). Exclusion Criteria: * known aneuploid anomaly, syndrome congenital infection. * If there is a plan to terminate the pregnancy.

What they're measuring

Umbilical artery Pulsatility index

Timeframe: between 24 gestational weeks until 36 weeks

Middle cerebral artery Pulsatility index

Timeframe: between 24 gestational weeks until 36 weeks

fetal abdominal circumference growth velocity

Timeframe: between 24 gestational weeks until 36 weeks

Trial details

NCT IDNCT03153215

SponsorBeni-Suef University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-12-31

View on ClinicalTrials.gov More Intra-Uterine Growth Retardation trials